Literature DB >> 15920487

Common 4q24 deletion in four cases of hematopoietic malignancy: early stem cell involvement?

F Viguié1, A Aboura, D Bouscary, S Ramond, A Delmer, G Tachdjian, J P Marie, N Casadevall.   

Abstract

We determined bone marrow karyotype at diagnosis in four female acute myeloid leukemia (AML) or myelodysplasia patients, aged between 52 and 56 years. In each case, we observed chromosome rearrangement involving the same 4q24 band. Three patients had a balanced reciprocal translocation as the sole abnormality - t(3;4)(q26;q24), t(4;5)(q24;p16) and t(4;7)(q24;q21) - and the fourth had del(4)(q23q24), +4. We used a set of 4q BAC probes for fluorescent in situ hybridization (FISH) in these four cases. We found a 4q24 submicroscopic deletion in all three translocations, with a common deletion of approximately 0.5 Mb. In three cases, we concluded that rearrangement occurred in an early hematopoietic stem cell, as it was detected, in mosaic with a normal karyotype, in a fraction of remission bone marrow cells, peripheral T and B lymphocytes, malignant lymph node T-lymphoma cells in one case and B-lymphoblastoid cell lines established in two cases. Moreover, one of 10 additional AML patients tested by FISH had a normal karyotype and deletion of one of the commonly deleted probe sequences. A tumor suppressor gene may therefore be involved, especially as two patients developed malignant lymphoma at the same time as myeloid proliferation. Leukemia (2005) 19, 1411-1415.

Entities:  

Mesh:

Year:  2005        PMID: 15920487     DOI: 10.1038/sj.leu.2403818

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  32 in total

1.  TET2 gene is not deleted in chronic myelomonocytic leukemia: a FISH retrospective study.

Authors:  Mar Mallo; Gemma Osca; Julia Solórzano; Leonor Arenillas; Lourdes Florensa; Francesc Solé
Journal:  Haematologica       Date:  2010-06-30       Impact factor: 9.941

Review 2.  Molecular aspects of myeloproliferative neoplasms.

Authors:  François Delhommeau; Dorota Jeziorowska; Christophe Marzac; Nicole Casadevall
Journal:  Int J Hematol       Date:  2010-02-27       Impact factor: 2.490

Review 3.  Molecular pathophysiology of myelodysplastic syndromes.

Authors:  R Coleman Lindsley; Benjamin L Ebert
Journal:  Annu Rev Pathol       Date:  2012-08-28       Impact factor: 23.472

4.  Role of TET2 mutations in myeloproliferative neoplasms.

Authors:  Elodie Pronier; François Delhommeau
Journal:  Curr Hematol Malig Rep       Date:  2012-03       Impact factor: 3.952

5.  Genome-wide profiling identifies a DNA methylation signature that associates with TET2 mutations in diffuse large B-cell lymphoma.

Authors:  Fazila Asmar; Vasu Punj; Jesper Christensen; Marianne T Pedersen; Anja Pedersen; Anders B Nielsen; Christoffer Hother; Ulrik Ralfkiaer; Peter Brown; Elisabeth Ralfkiaer; Kristian Helin; Kirsten Grønbæk
Journal:  Haematologica       Date:  2013-07-05       Impact factor: 9.941

Review 6.  Epigenetics of neurological cancers.

Authors:  Shaun D Fouse; Joseph F Costello
Journal:  Future Oncol       Date:  2009-12       Impact factor: 3.404

7.  Genome wide molecular analysis of minimally differentiated acute myeloid leukemia.

Authors:  Fernando P G Silva; Inês Almeida; Bruno Morolli; Geeske Brouwer-Mandema; Hans Wessels; Rolf Vossen; Harry Vrieling; Erik W A Marijt; Peter J M Valk; Hanneke C Kluin-Nelemans; Wolfgang R Sperr; Wolf-Dieter Ludwig; Micheline Giphart-Gassler
Journal:  Haematologica       Date:  2009-09-22       Impact factor: 9.941

8.  TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis.

Authors:  A Tefferi; A Pardanani; K-H Lim; O Abdel-Wahab; T L Lasho; J Patel; N Gangat; C M Finke; S Schwager; A Mullally; C-Y Li; C A Hanson; R Mesa; O Bernard; F Delhommeau; W Vainchenker; D G Gilliland; R L Levine
Journal:  Leukemia       Date:  2009-03-05       Impact factor: 11.528

9.  Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates.

Authors:  A Tefferi; R L Levine; K-H Lim; O Abdel-Wahab; T L Lasho; J Patel; C M Finke; A Mullally; C-Y Li; A Pardanani; D G Gilliland
Journal:  Leukemia       Date:  2009-03-05       Impact factor: 11.528

10.  Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1.

Authors:  Mamta Tahiliani; Kian Peng Koh; Yinghua Shen; William A Pastor; Hozefa Bandukwala; Yevgeny Brudno; Suneet Agarwal; Lakshminarayan M Iyer; David R Liu; L Aravind; Anjana Rao
Journal:  Science       Date:  2009-04-16       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.